Can the Cancer Vaccine Sipuleucel-T Sip the hell out of Cancers ?
Sipuleucel-T (Provenge) was the first therapeutic cancer vaccine to be approved by the FDA for Prostate cancers. Sipuleucel-T consists of Peripheral blood mononuclear cells (PBMCs) including Antigen presenting cells (APCs) was developed by Dendreon. The APCs that have been activated for a definite period in cell culture with recombinant protein containing Prostatic acid phosphatase (PAP) and Granuocyle macrophage colony stimulating factor (GM-CSF).
